Business

Jabil Circuit has announced the completion of its $665 million acquisition of contract plastics manufacturer Nypro, which makes dry powder inhalers and nasal spray pumps for pharmaceutical companies among other products. According to Jabil, it will keep the Nypro name and will absorb approximately 10,000 Nypro employees. Nypro will keep its headquarters in Clinton, … [Read more...] about Jabil completes acquisition of Nypro

Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015. Valeant will pay Zogenix a quarterly service fee based on a percentage of sales exceeding a specified baseline. Zogenix CEO Roger L. Hawley … [Read more...] about Zogenix to co-promote Migranal nasal spray in US

The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis. The team's research proposal was titled "A tight squeeze: … [Read more...] about RespiTech gets grant for inhaled pulmonary fibrosis treatment

Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary … [Read more...] about Kamada gets new patents for inhaled AAT

Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson's disease patients, the company said. The grant will support a Phase 2b trial of the carrier-free dry powder formulation. The foundation previously awarded … [Read more...] about Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation

Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and royalties. Calling the acquisition "a significant step toward expanding its respiratory pipeline," the company cited MicroDose’s proprietary dry … [Read more...] about MicroDose Therapeutx acquired by Teva

Shareholders of Elan Corporation have rejected the company's $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June 14 that it would put itself up for sale. Theravance CEO Rick Winningham responded to the vote saying, "While we are disappointed … [Read more...] about Elan shareholders reject Theravance deal

So many shareholders have already voted against Elan's proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan shareholders on June 17. Without citing any reason, Elan's board has now announced that it will proceed with the sale of the company, saying that … [Read more...] about Theravance deal in doubt, Elan board goes forward with sale process

AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if sales goals are met. Pearl announced the initiation of a Phase 3 program for its PT003 formoterol fumarate/glycopyrrolate MDI for the treatment of COPD in … [Read more...] about Pearl Therapeutics to be acquired by AstraZeneca

Finnish drug developer Biotie Therapies has announced that it is paying $1 million for an exclusive option to acquire Neurelis, Inc., which is developing NRL-1, an intranasal diazepam formulation for the treatment of epilepsy. The FDA cleared the IND for NRL-1 in February 2012. If Biotie exercises its option, it will pay $8.75 million for all outstanding shares of … [Read more...] about Biotie Therapies looks to acquire diazepam nasal spray